Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission | Zendy

Dara A. Lehman | Zendy; Michael H. Chung | Zendy; Jennifer Mabuka | Zendy; Grace JohnStewart | Zendy; James Kiarie | Zendy; John Kinuthia | Zendy; Julie Overbaugh | Zendy

Open Access

Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission

Author(s) -

Dara A. Lehman,

Michael H. Chung,

Jennifer Mabuka,

Grace JohnStewart,

James Kiarie,

John Kinuthia,

Julie Overbaugh

Publication year - 2009

Publication title -

jaids journal of acquired immune deficiency syndromes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.162

H-Index - 157

eISSN - 1944-7884

pISSN - 1525-4135

DOI - 10.1097/qai.0b013e3181aa8a22

Subject(s) - nevirapine , zidovudine , medicine , virology , breastfeeding , drug resistance , transmission (telecommunications) , viral load , virus , biology , viral disease , antiretroviral therapy , pediatrics , microbiology and biotechnology , electrical engineering , engineering

Antiretroviral resistance after short-course regimens used to prevent mother-to-child transmission has consequences for later treatment. Directly comparing the prevalence of resistance after short-course regimens of highly active antiretroviral therapy (HAART) and zidovudine plus single-dose nevirapine (ZDV/sdNVP) will provide critical information when assessing the relative merits of these antiretroviral interventions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research